Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

An avatar for precision cancer therapy

Screening patient-derived tumor cell cultures against a drug library is a promising adjunct to clinical decision-making.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1


  1. O'Brien, S.G. et al. N. Engl. J. Med. 348, 994–1004 (2003).

    Article  CAS  Google Scholar 

  2. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  3. Soria, J.C. et al. N. Engl. J. Med. 378, 113–125 (2018).

    Article  CAS  Google Scholar 

  4. Tsimberidou, A.M. et al. JCO Precis. Oncol. 2017, (2017).

  5. Wheler, J.J. et al. Cancer Res. 76, 3690–3701 (2016).

    Article  CAS  Google Scholar 

  6. Lee, J.-K. et al. Nat. Genet. 50, 1399–1411 (2018).

    Article  CAS  Google Scholar 

  7. Vlachogiannis, G. et al. Science 359, 920–926 (2018).

    Article  CAS  Google Scholar 

  8. Gao, H. et al. Nat. Med. 21, 1318–1325 (2015).

    Article  CAS  Google Scholar 

  9. Kodack, D.P. et al. Cell Rep. 21, 3298–3309 (2017).

    Article  CAS  Google Scholar 

  10. Jacobsen, E., Shanmugam, V. & Jagannathan, J. N. Engl. J. Med. 377, 2398–2399 (2017).

    Article  Google Scholar 

  11. Janku, F. et al. Cell Rep. 6, 377–387 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Razelle Kurzrock.

Ethics declarations

Competing interests

R.K. receives research funding from Genentech, Incyte, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, Konica Minolta, Grifols and Guardant, as well as receiving consultant fees from Loxo, X Biotech, NeoMed and Actuate Therapeutics, receiving speaker fees from Roche, and holding an ownership interest in IDbyDNA and Curematch Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kato, S., Kurzrock, R. An avatar for precision cancer therapy. Nat Biotechnol 36, 1053–1055 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer